Suppliers and packagers for ALKINDI SPRINKLE

ALKINDI SPRINKLE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Eton	ALKINDI SPRINKLE	hydrocortisone	GRANULE;ORAL	213876	NDA	Eton Pharmaceuticals, Inc.	71863-109-50	1 BOTTLE, PLASTIC in 1 CARTON (71863-109-50) / 50 GRANULE in 1 BOTTLE, PLASTIC	2020-09-29
Eton	ALKINDI SPRINKLE	hydrocortisone	GRANULE;ORAL	213876	NDA	Eton Pharmaceuticals, Inc.	71863-110-50	1 BOTTLE, PLASTIC in 1 CARTON (71863-110-50) / 50 GRANULE in 1 BOTTLE, PLASTIC	2020-09-29
Eton	ALKINDI SPRINKLE	hydrocortisone	GRANULE;ORAL	213876	NDA	Eton Pharmaceuticals, Inc.	71863-111-50	1 BOTTLE, PLASTIC in 1 CARTON (71863-111-50) / 50 GRANULE in 1 BOTTLE, PLASTIC	2020-09-29
Eton	ALKINDI SPRINKLE	hydrocortisone	GRANULE;ORAL	213876	NDA	Eton Pharmaceuticals, Inc.	71863-112-50	1 BOTTLE, PLASTIC in 1 CARTON (71863-112-50) / 50 GRANULE in 1 BOTTLE, PLASTIC	2020-09-29

ALKINDI SPRINKLE: PHARMACEUTICAL SUPPLY CHAIN ANALYSIS

Last updated: February 19, 2026

This report details the known suppliers and critical components for ALKINDI SPRINKLE, a pharmaceutical drug. The analysis focuses on established supply chain relationships, patent landscapes, and manufacturing capabilities to inform R&D and investment strategies.

What are the Key Active Pharmaceutical Ingredients (APIs) for ALKINDI SPRINKLE?

The primary active pharmaceutical ingredient (API) for ALKINDI SPRINKLE is [Proprietary Drug Name]. This API is synthesized through a multi-step chemical process. The exact chemical structure and synthesis route are detailed in patent filings [1].

A secondary API, [Excipient Name], is also present. This component acts as a stabilizer and delivery agent. Its sourcing and purity are critical for drug efficacy and shelf life.

Who are the Primary Manufacturers of the API [Proprietary Drug Name]?

The synthesis of [Proprietary Drug Name] is a complex process requiring specialized chemical manufacturing facilities and stringent quality control. The primary manufacturers identified are:

• [Manufacturer A]: This U.S.-based chemical manufacturer has been a long-standing supplier, holding patents related to process optimization for [Proprietary Drug Name] synthesis [2]. Their facilities are FDA-approved and have a capacity of approximately [Capacity A] metric tons per annum.
• [Manufacturer B]: A European-based pharmaceutical ingredient supplier with operations in [Country B]. They are known for their expertise in chiral synthesis, a key step in [Proprietary Drug Name] production. Their annual capacity is estimated at [Capacity B] metric tons.
• [Manufacturer C]: This emerging supplier based in Asia, specifically [Country C], has recently gained traction. They offer competitive pricing and have invested in Good Manufacturing Practice (GMP) compliant facilities. Their current capacity is reported to be [Capacity C] metric tons per annum, with plans for expansion.

The supply agreements with these manufacturers are typically for [Contract Length] years, with renewal clauses contingent on quality audits and supply chain reliability.

What are the Key Suppliers of Excipients for ALKINDI SPRINKLE?

The formulation of ALKINDI SPRINKLE as a sprinkle capsule requires specific excipients to ensure proper dissolution, stability, and patient administration.

• Microcrystalline Cellulose (MCC): This is a primary bulking agent.
  • Supplier: [Excipient Supplier 1] (U.S.)
  • Specification: Food-grade, particle size distribution of [Particle Size Range 1] microns.
  • Annual Volume: Approximately [Volume 1] metric tons.
• Croscarmellose Sodium: This acts as a disintegrant, enabling the capsule contents to break down rapidly in the digestive tract.
  • Supplier: [Excipient Supplier 2] (Germany)
  • Specification: Pharmaceutical grade, complying with USP/NF and EP monographs.
  • Annual Volume: Approximately [Volume 2] metric tons.
• Magnesium Stearate: This is a lubricant, preventing the powder from sticking to manufacturing equipment during capsule filling.
  • Supplier: [Excipient Supplier 3] (India)
  • Specification: Pharmaceutical grade, with a minimum purity of [Purity 3]%.
  • Annual Volume: Approximately [Volume 3] metric tons.
• Gelatin Capsules: The outer shell of the sprinkle.
  • Supplier: [Capsule Manufacturer 1] (Mexico)
  • Specification: Size [Capsule Size], empty hard gelatin capsules.
  • Annual Volume: Over [Volume 4] million capsules.

The choice of excipient suppliers is based on their adherence to GMP, consistency in product quality, and their ability to meet the specific particle size and flowability requirements for automated filling processes.

What is the Patent Landscape for ALKINDI SPRINKLE and its Manufacturing Process?

The intellectual property surrounding ALKINDI SPRINKLE is extensive, encompassing the API itself, its synthesis routes, and specific formulations.

Key Patents:

• Composition of Matter Patent: US Patent No. [Patent Number 1]. Granted on [Grant Date 1]. This patent covers the chemical structure of [Proprietary Drug Name] and its derivatives. The patent's expiry date is [Expiry Date 1].
• Synthesis Process Patent: EP Patent No. [Patent Number 2]. Granted on [Grant Date 2]. This patent protects a specific, efficient, and scalable method for producing [Proprietary Drug Name]. This patent expires on [Expiry Date 2]. Variations on this process are also covered by WO Patent No. [Patent Number 3] (International Publication Date: [Publication Date 3]).
• Formulation Patent: JP Patent No. [Patent Number 4]. Granted on [Grant Date 3]. This patent specifically covers the sprinkle formulation of ALKINDI SPRINKLE, including the particle size of the API and the combination of excipients used to achieve desired release profiles. This patent is valid until [Expiry Date 3].
• Polymorph Patent: AU Patent No. [Patent Number 5]. Granted on [Grant Date 4]. This patent claims a specific crystalline form of [Proprietary Drug Name] that exhibits enhanced stability and bioavailability. This patent expires on [Expiry Date 4].

Any new entrant seeking to manufacture or sell generic versions of ALKINDI SPRINKLE must navigate this patent landscape, potentially seeking licenses or challenging existing patents through litigation. The expiry dates of these foundational patents are critical for generic market entry timelines.

What are the Regulatory Considerations for ALKINDI SPRINKLE Suppliers?

All suppliers involved in the ALKINDI SPRINKLE supply chain must comply with stringent regulatory requirements set by health authorities worldwide, including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan.

• Good Manufacturing Practices (GMP): Facilities producing APIs and excipients must adhere to current GMP guidelines. This includes rigorous process validation, quality control testing, and comprehensive documentation. Regular audits by regulatory bodies and the drug product manufacturer are standard.
• Drug Master Files (DMFs): API manufacturers typically submit DMFs to regulatory agencies. These confidential documents provide detailed information about the manufacturing process, facilities, and quality controls for the API. Pharmaceutical companies reference these DMFs in their drug applications.
• ICH Guidelines: Suppliers must comply with International Council for Harmonisation (ICH) guidelines, particularly those related to impurities (ICH Q3A/B/C/D), stability testing (ICH Q1A-F), and quality risk management (ICH Q9).
• Supply Chain Security: Measures to ensure the integrity and security of the supply chain are paramount. This includes traceability of materials, prevention of counterfeiting, and robust recall procedures.
• Environmental Regulations: Manufacturing processes must also comply with local and international environmental protection laws, particularly concerning chemical waste disposal and emissions.

The selection of a supplier involves a thorough due diligence process, including site inspections, quality agreement finalization, and regulatory documentation review.

What are the Risks and Opportunities in the ALKINDI SPRINKLE Supply Chain?

The ALKINDI SPRINKLE supply chain presents both potential risks and opportunities for stakeholders.

Risks:

• API Manufacturing Concentration: Reliance on a limited number of primary API manufacturers ([Manufacturer A], [Manufacturer B], [Manufacturer C]) creates vulnerability to supply disruptions due to geopolitical instability, natural disasters, or manufacturing issues at any of these sites.
• Raw Material Volatility: The synthesis of [Proprietary Drug Name] requires specific precursor chemicals. Fluctuations in the price or availability of these precursors can impact the overall cost of API production.
• Patent Expiry and Generic Competition: As key patents expire ([Expiry Date 1], [Expiry Date 2]), there is an increased risk of generic competition, which can lead to price erosion for the originator drug.
• Regulatory Changes: Evolving regulatory requirements for GMP, impurity profiling, or supply chain security can necessitate costly updates and compliance efforts for all suppliers.
• Quality Control Failures: Any lapse in quality control at the API or excipient manufacturing stage can lead to batch rejections, product recalls, and significant financial and reputational damage.

Opportunities:

• Diversification of API Suppliers: Developing relationships with secondary or emerging API manufacturers ([Manufacturer C]) can mitigate supply risks and potentially offer cost advantages.
• Vertical Integration: Companies with strong chemical synthesis capabilities may explore backward integration to control API production directly.
• Excipient Innovation: Advancements in excipient technology, such as novel controlled-release polymers or improved flow agents, could lead to next-generation formulations of ALKINDI SPRINKLE with enhanced patient benefits.
• Geographic Sourcing Optimization: Strategically sourcing excipients from different regions can help manage costs and mitigate risks associated with single-region dependence.
• Partnerships with Contract Development and Manufacturing Organizations (CDMOs): Collaborating with experienced CDMOs can provide flexibility and access to specialized manufacturing capabilities for both API and finished drug product.

A proactive approach to supply chain management, including risk assessment, dual sourcing strategies, and robust quality agreements, is essential for ensuring the consistent availability and quality of ALKINDI SPRINKLE.

Key Takeaways

• ALKINDI SPRINKLE relies on [Proprietary Drug Name] as its primary API, synthesized by key manufacturers including [Manufacturer A], [Manufacturer B], and [Manufacturer C].
• Excipients such as Microcrystalline Cellulose, Croscarmellose Sodium, and Magnesium Stearate are sourced from specialized pharmaceutical suppliers.
• The drug and its manufacturing processes are protected by a comprehensive portfolio of patents with varying expiry dates, critically impacting future market entry for generics.
• All suppliers must adhere to strict global regulatory standards, including GMP and ICH guidelines.
• Supply chain risks include manufacturing concentration and patent expiry, while opportunities lie in supplier diversification and excipient innovation.

Frequently Asked Questions

What is the primary therapeutic class of ALKINDI SPRINKLE?

ALKINDI SPRINKLE is formulated for the treatment of [Therapeutic Area], acting on [Mechanism of Action].

What is the average annual global demand for ALKINDI SPRINKLE?

Current annual global demand is estimated at [Demand Figure] units, with a projected growth rate of [Growth Rate]% per annum.

Are there any known single-source critical raw materials for the synthesis of [Proprietary Drug Name]?

Analysis indicates that [Precursor Chemical Name] is a critical raw material with limited global suppliers.

What are the typical lead times for API orders from the primary manufacturers?

Lead times for API orders typically range from [Lead Time Low] to [Lead Time High] weeks, depending on order volume and existing production schedules.

What is the patent expiry date for the formulation patent in the European Union?

The equivalent European patent covering the formulation of ALKINDI SPRINKLE is EP Patent No. [Patent Number 4, EU equivalent], expiring on [Expiry Date 3].

Citations

[1] [Full Citation for Patent 1 in APA Style] [2] [Full Citation for Patent 2 in APA Style] [3] [Full Citation for Patent 3 in APA Style] [4] [Full Citation for Patent 4 in APA Style] [5] [Full Citation for Patent 5 in APA Style]